## Interview Summary

10/553,324	NEW, ROGER R. C.		
Examiner	Art Unit	-	
Hemant Khanna	1654		

	Hemant Khan	na	1654			
All participants (applicant, applicant's representative, PTO	personnel):					
(1) <u>Hemant Khanna</u> .	(3) <u>Roger F</u>	(3)Roger R. C. New.				
(2) Art Crawford.	(4)	(4)				
Date of Interview: <u>17 May 2007</u> .						
Type: a)☐ Telephonic b)☐ Video Conference c)☒ Personal [copy given to: 1)☒ applicant 2	2) applicant	s representative	]			
oit shown or demonstration conducted: d) Yes e) No. f Yes, brief description:						
m(s) discussed: <u>30-58</u> .						
Identification of prior art discussed: None.						
Agreement with respect to the claims f)⊠ was reached. g	ı)∏ was not re	eached. h) N	/A.			
Substance of Interview including description of the general reached, or any other comments: Amending the active made only to overcome written description rejection. Amending a methods of using the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the amending and the pharmaceutical composition. Amending a methods of the pharmaceutical composition. Amending a method of the pharmaceutical composition and the pharmaceutical composition. Amending a method of the pharmaceutical composition and the pharmaceutical composition. Amending a method of the p	Ing claims to read of the copy of the amod.)  ACTION MUST Last Office act OF ONE MORE	continciple to read on an oral pharm define novelty of the examiner agendments that we will include the tion has already with OR THIRTY MARY FORM,	on polypeptides naceutical composition the composition reed would render the substance of been filed, APP DAYS FROM TWHICHEVER IS	er the claims claims CF THE LICANT IS THIS LATER, TO		
requirements on reverse side or on attached sheet.						
		:				
	· .					
		anh	رج ب	ί,		
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.		Examiner's sign	ature, if required	<u></u>		

U.S. Patent and Trademark Office PTOL-413 (Rev. 04-03)

Interview Summary

Paper No. 20070517